SpicyIP Tidbit: Analysing the Mankind Pharma Order through the lens of the Modi Pharma Case on the ‘Family of Marks Doctrine’
[This post is authored by Bhavya Gupta. Bhavya is a third year BA. LLB student at the National Law School of India University, Bangalore. Her academic and professional interests lie in corporate law, intellectual property, competition law and international arbitration.] The Delhi High Court recently in Mankind Pharma Ltd. v. Ram Kumar M/s Dr. Kumars Pharmaceuticals (C.O. (COMM.IPD-TM) 566/2022) ordered for the cancellation of the “UNKIND” mark in Class 35, providing a useful opportunity to reflect on the judicial reading […]










